Projects we fund

Overview

Osteosarcoma (OS) is the most common type of bone tumour in children and young adults. It is caused by the abnormal growth of bone cells. Only around 65% of children with OS survive for five years or more and survival rates have improved little over the past four decades. Better treatments are desperately needed. New, more effective, drugs could be designed to target specific molecules (‘vulnerabilities’) in a child’s OS cells, but this requires a detailed understanding of the functions and mechanisms of such target molecules. In this pilot study, Dr John Murphy and his team are exploring the therapeutic potential of a newly-identified potential weakness in OS cells, represented by a protein called ZFP36L1. Dr Murphy and his team have been studying ZFP36L1 for many years and have some preliminary evidence from the laboratory that inhibiting this protein may reduce OS cell survival and make OS cells more susceptible to traditional anti-cancer drugs, but more research is needed to confirm this. In this pilot laboratory study, Dr Murphy and his team will take the next steps to explore the function of ZFP36L1 and as a potential treatment target in OS. This will involve using gene-editing technology to remove the gene for ZFP36L1 from human OS cells in a “test-tube” setting, so the cells can no longer make the protein. The researchers will observe the impact that taking ZFP36L1 away has on cell function, gene activity, survival and drug resistance. Dr Murphy and his team will repeat this experiment across different OS cells, including those representing aggressive versions of the disease. This work will be essential to understand the function of ZFP36L1, its role in OS and whether it would make a suitable target for new anti-OS drugs that could make existing drugs more effective.

What difference will this project make?

Better treatments for OS are desperately needed. This pilot laboratory study aims to verify whether ZFP36L1 could be a suitable target for the development of new targeted anti-OS drugs that could make existing drugs more effective. While this work will still take several years to reach patients, seed-funding early-phase research such as this is essential for nurturing the new discoveries that could benefit patients in the future.